Search Results 441-450 of 24292 for B cell lymphomas
... B-cell Lymphoma (R/R DLBCL). Rochester, Minn. Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by ...
... b-cell lymphoma (DLBCL) patients with out of ... cell lymphoma that has come back or does not respond to treatment. ... A virus, called VSV-hIFNbeta-NIS, which has ...
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025 Oct 30; 146(18):2177-2188. View PubMed ...
Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma. Rochester, Minn., La Crosse, Wis., Mankato ...
NOTE: patients with B-cell lymphoma with features intermediate between diffuse large B ... Relapsed/refractory primary vitreoretinal diffuse large B cell lymphoma ...
BTK inhibitors work by blocking the B-cell receptor signaling pathway. Then in 2016, the FDA approved the first B-cell lymphoma 2 (BCL-2) inhibitor drug for the ...
Large B-cell lymphoma with IRF4 gene rearrangements: Differences in clinicopathologic, immunophenotypic and cytogenetic features between pediatric and adult ...
Marginal zone lymphoma, B-cell lymphoma, Lymphoma, Hairy cell leukemia, T-cell lymphoma, Small lymphocytic lymphoma, Follicular lymphoma, Hodgkin lymphoma ...
This study is being performed to understand the causes of drug resistance and to improve the treatment options for patients diagnosed with B-cell cancers. We ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!